103.63

1.75% 1.78

Spyre Therapeutics Inc (SYRE)

Overview News Price History Financials Discussions Forecast

Spyre Therapeutics Inc stock is traded at $103.63, with a volume of 559.30K. It is up +1.75% in the last 24 hours and up +4.73% over the past month. Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Previous Close:

$101.85

Open:

$101.21

24h Volume:

559.30K

Relative Volume:

0.46

Market Cap:

$9.14B

Revenue:

$688.00K

Net Income/Loss:

$-168.74M

P/E Ratio:

-43.95

EPS:

-2.3577

Net Cash Flow:

$-185.87M

1W Performance:

-1.22%

1M Performance:

+4.73%

6M Performance:

+182.91%

1Y Performance:

+514.65%

1-Day Range:

$95.61

$104.13

1-Week Range:

$95.61

$107.00

52-Week Range:

$14.51

$108.14

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name

Spyre Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(617) 651-5940

Address

221 CRESCENT STREET, WALTHAM

Employee

112

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

SYRE's Discussions on Twitter

Compare SYRE vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SYRE Spyre Therapeutics Inc	103.63	9.18B	688.00K	-168.74M	-185.87M	-2.3577
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Raymond James	Strong Buy
Dec-18-25	Initiated	Mizuho	Outperform
Dec-17-25	Initiated	Citigroup	Buy
Sep-26-25	Initiated	Deutsche Bank	Buy
Apr-08-25	Initiated	Leerink Partners	Outperform
Mar-18-25	Initiated	Wolfe Research	Outperform
Sep-04-24	Initiated	Wedbush	Outperform
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-20-23	Initiated	BTIG Research	Buy
Dec-11-23	Initiated	Guggenheim	Buy
Dec-11-23	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
Mar-21-19	Initiated	JP Morgan	Overweight
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform
Mar-14-18	Reiterated	Needham	Buy

View All

Spyre Therapeutics Inc Stock (SYRE) Latest News

Aug 14, 2026

Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund - Stock Titan

Aug 14, 2026

RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds - Stock Titan

Aug 14, 2026

Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat

Aug 14, 2026

Aug 13, 2026

Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside - TradingView

Aug 13, 2026

Aug 11, 2026

Price to earnings forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView

Aug 11, 2026

Price to book forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView

Aug 11, 2026

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat

Aug 11, 2026

SYRE Maintained by BTIG -- Price Target Raised to $132.00 - GuruFocus

Aug 11, 2026

Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares - Bitget

Aug 11, 2026